Literature DB >> 17201154

Reduced heterochromatin protein 1-beta (HP1beta) expression is correlated with increased invasive activity in human melanoma cells.

Keisuke Nishimura1, Yoshifumi S Hirokawa, Hitoshi Mizutani, Taizo Shiraishi.   

Abstract

Heterochromatin protein 1 (HP1) is associated with heterochromatin formation and the regulation of gene expression. In this study, we demonstrated that decreased HP1beta, but not HPla, mRNA and protein expression, correlates with invasive potential in five human melanoma cell lines, and we used immunohistochemistry to confirm that HP1beta expression is suppressed during melanoma progression. HPIP levels are decreased in (V600E)B-RAF-transformed mouse melanocytes, suggesting that HP1beta-mediated suppressive mechanisms correlate with melanoma oncogenesis. Expression of microphthalmia associated-transcription factor (MITF), an important melanocyte differentiation factor, is reduced in melanoma, which is correlated with poor prognosis. In CRL1579, SK-MEL-28 and HMV-II human melanoma cells in which HP1beta expression is reduced by RNAi, MITF RNA levels and invasiveness activities are differentially altered and are not correlated with each other. Our findings indicate that the (V600E)B-RAF mutation induces HPIbeta down-regulation, which causes epigenetic gene regulation associated with melanoma progression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17201154

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Gastrin-releasing peptide signaling alters colon cancer invasiveness via heterochromatin protein 1Hsβ.

Authors:  Robert Tell; Claudio A Rivera; Jillian Eskra; Lauren N Taglia; Adam Blunier; Q Tian Wang; Richard V Benya
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 2.  Structure and mechanisms of lysine methylation recognition by the chromodomain in gene transcription.

Authors:  Kyoko L Yap; Ming-Ming Zhou
Journal:  Biochemistry       Date:  2011-02-23       Impact factor: 3.162

3.  Heterochromatin protein 1 expression is reduced in human thyroid malignancy.

Authors:  Maria S Tretiakova; Sarah D Bond; David Wheeler; Alejandro Contreras; Masha Kocherginsky; Todd G Kroll; Tracy K Hale
Journal:  Lab Invest       Date:  2014-05-19       Impact factor: 5.662

4.  Sequence-specific recruitment of heterochromatin protein 1 via interaction with Krüppel-like factor 11, a human transcription factor involved in tumor suppression and metabolic diseases.

Authors:  Gwen Lomberk; Angela J Mathison; Adrienne Grzenda; Seungmae Seo; Cathrine J DeMars; Sumera Rizvi; Juliana Bonilla-Velez; Ezequiel Calvo; Martin E Fernandez-Zapico; Juan Iovanna; Navtej S Buttar; Raul Urrutia
Journal:  J Biol Chem       Date:  2012-02-08       Impact factor: 5.157

5.  Identification of ChIP-seq mapped targets of HP1β due to bombesin/GRP receptor activation.

Authors:  Robert Tell; Q Tian Wang; Adam Blunier; Richard V Benya
Journal:  Clin Epigenetics       Date:  2011-03-29       Impact factor: 6.551

Review 6.  Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy.

Authors:  Stuart J Gallagher; Jessamy C Tiffen; Peter Hersey
Journal:  Cancers (Basel)       Date:  2015-09-25       Impact factor: 6.639

7.  Expression of HPIP in epithelial ovarian carcinoma: a clinicopathological study.

Authors:  Yuping Wang; Fanling Meng; Yunduo Liu; Xiuwei Chen
Journal:  Onco Targets Ther       Date:  2016-12-20       Impact factor: 4.147

Review 8.  Heterochromatin Protein 1: A Multiplayer in Cancer Progression.

Authors:  Yu Hyun Jeon; Go Woon Kim; So Yeon Kim; Sang Ah Yi; Jung Yoo; Ji Yoon Kim; Sang Wu Lee; So Hee Kwon
Journal:  Cancers (Basel)       Date:  2022-02-01       Impact factor: 6.639

9.  HPIP: a predictor of lymph node metastasis and poor survival in cervical cancer.

Authors:  Shan Cao; Jingxia Sun; Shuai Lin; Lu Zhao; Di Wu; Tian Liang; Wenji Sheng
Journal:  Onco Targets Ther       Date:  2017-08-26       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.